[go: up one dir, main page]

CN115836068A - 吡咯烷类化合物及其应用 - Google Patents

吡咯烷类化合物及其应用 Download PDF

Info

Publication number
CN115836068A
CN115836068A CN202180035358.6A CN202180035358A CN115836068A CN 115836068 A CN115836068 A CN 115836068A CN 202180035358 A CN202180035358 A CN 202180035358A CN 115836068 A CN115836068 A CN 115836068A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180035358.6A
Other languages
English (en)
Other versions
CN115836068B (zh
Inventor
古鹏
刘磊
张国宝
周峰
唐任宏
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Zaiming Pharmaceutical Co ltd
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd, Simcere Pharmaceutical Co Ltd filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Priority to CN202510564066.1A priority Critical patent/CN120665066A/zh
Publication of CN115836068A publication Critical patent/CN115836068A/zh
Application granted granted Critical
Publication of CN115836068B publication Critical patent/CN115836068B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

公开了一种如式(I)所示吡咯烷类化合物或其药学可接受的盐，含有它们的药物组合物及其作为选择性雌激素受体降解剂(SERD)在预防或治疗雌激素受体相关疾病中的用途。
Figure DDA0003944440970000011

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180035358.6A 2020-05-15 2021-05-14 吡咯烷类化合物及其应用 Active CN115836068B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510564066.1A CN120665066A (zh) 2020-05-15 2021-05-14 吡咯烷类化合物及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020104140139 2020-05-15
CN202010414013 2020-05-15
PCT/CN2021/093736 WO2021228210A1 (zh) 2020-05-15 2021-05-14 吡咯烷类化合物及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510564066.1A Division CN120665066A (zh) 2020-05-15 2021-05-14 吡咯烷类化合物及其应用

Publications (2)

Publication Number Publication Date
CN115836068A true CN115836068A (zh) 2023-03-21
CN115836068B CN115836068B (zh) 2025-06-03

Family

ID=78526000

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510564066.1A Pending CN120665066A (zh) 2020-05-15 2021-05-14 吡咯烷类化合物及其应用
CN202180035358.6A Active CN115836068B (zh) 2020-05-15 2021-05-14 吡咯烷类化合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510564066.1A Pending CN120665066A (zh) 2020-05-15 2021-05-14 吡咯烷类化合物及其应用

Country Status (7)

Country Link
US (1) US20230348459A1 (zh)
EP (1) EP4151636A4 (zh)
JP (1) JP7720906B2 (zh)
CN (2) CN120665066A (zh)
AU (1) AU2021269612A1 (zh)
CA (1) CA3178707A1 (zh)
WO (1) WO2021228210A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240208932A1 (en) 2021-07-15 2024-06-27 Xizang Haisco Pharmaceutical Co., Ltd. Arylamino derivative estrogen receptor modulator and use thereof
WO2023083292A1 (zh) * 2021-11-12 2023-05-19 先声药业有限公司 吡咯烷类化合物的盐、晶型及其制备方法
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CA3261772A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen Receptor Modulators and Their Uses
CN120112288A (zh) * 2022-10-28 2025-06-06 南京再明医药有限公司 用于治疗肿瘤的药物组合、药物组合物及其用途
WO2025175249A1 (en) * 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108611A (zh) * 2014-12-18 2017-08-29 豪夫迈·罗氏有限公司 四氢‑吡啶并[3,4‑b]吲哚雌激素受体调节剂及其用途
CN107428758A (zh) * 2015-11-12 2017-12-01 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
WO2017216279A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
US20180111931A1 (en) * 2016-10-24 2018-04-26 Astrazeneca Ab Chemical compounds
CN109963848A (zh) * 2016-11-17 2019-07-02 赛诺菲 新颖的取代的n-(3-氟丙基)-吡咯烷化合物、其制备方法以及其治疗用途
WO2019223715A1 (zh) * 2018-05-23 2019-11-28 江苏恒瑞医药股份有限公司 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
WO2019245974A1 (en) * 2018-06-21 2019-12-26 Genentech, Inc. Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147924A1 (en) * 2008-07-24 2010-01-27 Bayer Schering Pharma Aktiengesellschaft Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
WO2015136017A1 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
CN109415361B (zh) * 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2019002442A1 (en) 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108611A (zh) * 2014-12-18 2017-08-29 豪夫迈·罗氏有限公司 四氢‑吡啶并[3,4‑b]吲哚雌激素受体调节剂及其用途
CN107428758A (zh) * 2015-11-12 2017-12-01 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
WO2017216279A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
US20180111931A1 (en) * 2016-10-24 2018-04-26 Astrazeneca Ab Chemical compounds
CN109963848A (zh) * 2016-11-17 2019-07-02 赛诺菲 新颖的取代的n-(3-氟丙基)-吡咯烷化合物、其制备方法以及其治疗用途
WO2019223715A1 (zh) * 2018-05-23 2019-11-28 江苏恒瑞医药股份有限公司 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
WO2019245974A1 (en) * 2018-06-21 2019-12-26 Genentech, Inc. Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use

Also Published As

Publication number Publication date
JP7720906B2 (ja) 2025-08-08
EP4151636A1 (en) 2023-03-22
WO2021228210A1 (zh) 2021-11-18
CA3178707A1 (en) 2021-11-18
US20230348459A1 (en) 2023-11-02
CN115836068B (zh) 2025-06-03
CN120665066A (zh) 2025-09-19
AU2021269612A1 (en) 2023-01-05
EP4151636A4 (en) 2024-02-28
JP2023526568A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
CN115836068A (zh) 吡咯烷类化合物及其应用
WO2022017339A1 (zh) 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
CN111902417B (zh) 一种二芳基巨环化合物、药物组合物以及其用途
CN116888128A (zh) 嘧啶并芳香环类化合物
CN114728938A (zh) 作为prmt5抑制剂的四氢异喹啉螺环化合物
CN113149993A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
EP4389752A1 (en) Camptothecin derivative, and pharmaceutical composition and use thereof
EP4365183A1 (en) Steroid compound, and pharmaceutical composition thereof and use thereof
CA3055258A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
TW202506682A (zh) 二胺基環戊基取代的雜芳基衍生物及其用途和製備方法
EP4177247A1 (en) Heterocyclic immunomodulator
CN113825757A (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
WO2023083283A1 (zh) 用于治疗肿瘤的药物组合及其应用
CN111630047B (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
TW202102511A (zh) 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
WO2021078227A1 (zh) 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
AU2024281173A1 (en) Compounds for the degradation of egfr kinase
CN118255713B (zh) 一种萘酰胺类化合物、其制备方法及其应用
WO2026032213A1 (zh) 取代的三环衍生物及其应用
WO2024207945A1 (zh) 作为aak1抑制剂的氮杂环类化合物
WO2024153158A1 (zh) 吡唑类衍生物、其药学上可接受的盐、立体异构体、药物组合物以及应用
HK40064826A (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
WO2023081463A1 (en) Deuterated (trifluoromethyl)pyrimidine-2-amine compounds as potentiators of the hmrgx1 receptor
WO2022166610A1 (zh) 一类哒嗪酮杂环化合物及其制备方法和用途
KR20250069999A (ko) Tyk2 억제제로서의 치환된 피리다진-3-카르복스아미드 화합물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231103

Address after: No. 99 Huakang Road, Jiangbei New District, Nanjing, Jiangsu Province, 211800

Applicant after: Nanjing Zaiming Pharmaceutical Co.,Ltd.

Address before: 210032 No.99, Huakang Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: SIMCERE PHARMACEUTICAL Co.,Ltd.

Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant